Click here to print this page

Planning Retirement Online

Cancer wonder drug not available on NHS

If you read this week’s Daily Mail, you will have seen the story that NICE (Britain’s National Institute for Health and Care Excellence) has announced that the new cancer wonder drug Nivolumab is too expensive and so won’t be available in England and Wales.

Nivolumab has shown to be twice as effective as chemotherapy with far fewer side effects.

To be told you have a life threatening disease is of course totally devastating. But to then be told there is a drug that could help or even stop it progressing, but you can’t have it because Britain can’t afford the cost must be even more shattering.

But here at Laterlife we remembered a breaking story just last July when it was announced that Nivolumab had been approved for lung cancer through the UK’s early access to medicine’s scheme and had been given an EU license for melanoma.

So does this mean that some patients can still have access to this breakthrough treatment.

Laterlife decided to find out the facts and contacted NICE.

They told Laterlife:

“Our independent advisory committee recognised that Nivolumab is a promising new treatment. However, even allowing for the extra flexibility they have for making recommendations about new cancer treatments, it could not be considered a cost effective use of NHS resources.”

However, NICE  has also told us that they are today (Dec 16th) opening a consultation on  preliminary draft guidance on Nivolumab (marketed as Opdivo by Bristol-Myers Squibb) to treat a specific type of lung cancer known as squamous cell, which is advanced or has spread to other areas of the body in adults whose disease has progressed after chemotherapy.

They said:

“Consultees, including the manufacturer, healthcare professionals and members of the public are now able to comment on the preliminary guidance. Comments received during this consultation will be fully considered by the Committee and following this meeting the next draft guidance will be issued.

“Until final guidance is issued, NHS bodies should make decisions locally on the funding of specific treatments. Once NICE issues its final guidance on a technology, it replaces local recommendations across the country.

 

Back to LaterLife Interest Index


Bookmark This Share on Facebook Receive more like this

 

Latest Articles:

Health food of the month - Haggis

haggis

Most people have heard of haggis; the traditional Scottish dish that is closely associated with Burns night in January each year. But what exactly is a haggis and is it good for you?

AXA Health: 7 common causes of swollen ankles and how they can be treated

healthy feet and ankles with smiley faces on the bottom

Swollen ankles can be unsightly, uncomfortable and can cause some distress. Getting to the bottom of what’s causing the swelling is important in order to treat the problem effectively.

Sit up straight and walk tall! Posture is important!

woman in pain holding her lower back

One thing so many people suffer from as they get older is poor posture. For those lucky enough not to have any back pain, slouching is still a really bad idea that can be setting up problems for the future.

more

Can the NHS survive?

doctor checking patient's blood pressure

Most of us have lived all our lives with the National Health Service and it can be a surprise to realise that until it was introduced some people simply couldn’t afford medical treatment. Can you imagine what that would be like?

Back to LaterLife Health Section

Visit our Pre-retirement Courses section here on laterlife or our dedicated Retirement Courses site

Bookmark


Advertise on laterlife.com



LaterLife Travel Insurance in Association with Avanti